13.23
-0.43(-3.15%)
Currency In USD
| Previous Close | 13.66 |
| Open | 13.65 |
| Day High | 13.75 |
| Day Low | 13.13 |
| 52-Week High | 76 |
| 52-Week Low | 4.56 |
| Volume | 26,216 |
| Average Volume | 50,112 |
| Market Cap | 59.82M |
| PE | -4.73 |
| EPS | -2.8 |
| Moving Average 50 Days | 14.4 |
| Moving Average 200 Days | 11.51 |
| Change | -0.43 |
If you invested $1000 in MiNK Therapeutics, Inc. (INKT) since IPO date, it would be worth $110.25 as of November 08, 2025 at a share price of $13.23. Whereas If you bought $1000 worth of MiNK Therapeutics, Inc. (INKT) shares 3 years ago, it would be worth $527.09 as of November 08, 2025 at a share price of $13.23.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025
GlobeNewswire Inc.
Yesterday at 2:00 PM GMT
Durable survival and deep, lasting remissions in checkpoint-refractory, heavily pretreated cancers with median OS of ~23 months with agenT-797 plus anti-PD-1Evidence of immune activation and tumor-immune remodeling underscore agenT-797’s potential to
MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development
GlobeNewswire Inc.
Nov 05, 2025 2:07 PM GMT
NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announ
MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
GlobeNewswire Inc.
Oct 30, 2025 1:00 PM GMT
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announ